Dassault Systemes in Talks to Acquire ArisGlobal

French software company Dassault Systemes is in discussions to acquire ArisGlobal, a drug trial software developer. According to a report by the Financial Times, this potential deal is seen as part of Dassault Systemes' strategy to expand its presence in the healthcare sector. ArisGlobal develops software used by pharmaceutical companies to manage clinical trials. The company's software aims to accelerate the drug development process by automating tasks such as collecting, analyzing, and reporting trial data. Dassault Systemes is known for its 3D design and product lifecycle management software. The company has recently drawn attention for its investments in the health and life sciences field. This acquisition could contribute to Dassault Systemes' growth targets in this area. While financial details of the deal have not yet been disclosed, it is noted that discussions are ongoing and, if finalized, would be subject to regulatory approvals. Officials from Dassault Systemes and ArisGlobal have not made any official statements on the matter. This is not investment advice.